Related Experiment Video
Updated: Jan 31, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
Donald C Moore1, Lesli A Lavery1
1Levine Cancer Institute, Atrium Health, Rock Hill, South Carolina; and Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Abstract:
Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regimens is appropriate and disease is not amenable to curative surgery or radiotherapy. It inhibits platelet-derived growth factor receptor alpha, leading to the inhibition of tumor cell proliferation, angiogenesis, and metastasis. In a phase II clinical trial, olaratumab in combination with doxorubicin met its predefined primary endpoint of improving progression-free survival and secondary endpoint of overall survival compared to doxorubicin monotherapy in patients with advanced soft-tissue sarcoma. Common adverse events associated with the combination of olaratumab and doxorubicin include nausea, mucositis, neutropenia, and infusion-related reactions.
Insights
Olaratumab plus doxorubicin demonstrated improved progression-free and overall survival in advanced soft-tissue sarcoma patients. This combination therapy offers a new treatment option for specific advanced sarcoma subtypes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced soft-tissue sarcomas are challenging to treat, often requiring novel therapeutic approaches.
- Olaratumab, a monoclonal antibody, targets platelet-derived growth factor receptor alpha (PDGFR-α).
Purpose of the Study:
- To evaluate the efficacy and safety of olaratumab in combination with doxorubicin for advanced soft-tissue sarcoma.
- To assess the impact on progression-free survival (PFS) and overall survival (OS).
Main Methods:
- A phase II clinical trial was conducted.
- Patients received either olaratumab plus doxorubicin or doxorubicin monotherapy.
Main Results:
- The combination therapy met its primary endpoint, significantly improving PFS.
- Overall survival was also improved compared to doxorubicin monotherapy.
- Common adverse events included nausea, mucositis, neutropenia, and infusion reactions.
Conclusions:
- Olaratumab in combination with doxorubicin shows promising efficacy for advanced soft-tissue sarcoma.
- This regimen represents a potential new treatment strategy for eligible patients.
Related Concept Videos
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods
Persuasion Strategies
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...

